Produktinformation
- Luxalbendazole
- methyl N-[5-(4-fluorophenyl)sulfonyloxy-3H-benzoimidazol-2-yl]carbamate
- 2-[(methoxycarbonyl)amino]-1H-benzimidazol-6-yl 4-fluorobenzenesulfonate
Luxabendazole is a benzimidazole compound that is used to treat parasitic worm infections. It works by inhibiting the activity of glutamate dehydrogenase and aminotransferases, which are enzymes that catalyze the metabolic pathways for amino acids. Luxabendazole has been shown to be effective in vivo against cancer cells, and it has been shown to inhibit the growth of tumor cells through its inhibition of glutamine synthetase and glutamate synthase. Luxabendazole can be administered orally or by injection. The elimination rate is rapid with a half-life of 2 hours. The effective dose is between 10-20 mg/kg body weight per day, with treatment lasting 7-14 days.